Langerhans cell histiocytosis and Erdheim-chester disease

Current Opinion in Rheumatology

Volumn 24, Issue 1, 2012, Pages 90-96

  Wilejto, Marta ^a   Abla, Oussama ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Erdheim Chester disease; Langerhans cell histiocytosis; Pathogenesis; Treatment

Indexed keywords

ALPHA INTERFERON; B RAF KINASE; BISPHOSPHONIC ACID DERIVATIVE; CLADRIBINE; CLOFARABINE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; IMATINIB; IMMUNOMODULATING AGENT; INDOMETACIN; INTERFERON; MERCAPTOPURINE; METHOTREXATE; METHYLPREDNISOLONE; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; THALIDOMIDE; VINBLASTINE; VINCRISTINE;

CELL MIGRATION; CELL PROLIFERATION; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); CYTOKINE PRODUCTION; DISEASE CLASSIFICATION; ERDHEIM CHESTER DISEASE; GENE MUTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTIOCYTE; HISTIOCYTOSIS; HISTIOCYTOSIS X; HUMAN; IMMUNOREGULATION; PATHOGENESIS; PHOTOCHEMOTHERAPY; PRIORITY JOURNAL; PUVA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REDUCED INTENSITY CONDITIONING; REVIEW; SURVIVAL TIME;

ERDHEIM-CHESTER DISEASE; HISTIOCYTOSIS, LANGERHANS-CELL; HUMANS;

EID: 82955203659     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0b013e32834db53e     Document Type: Review

References (68)

1. Weitzman S, Egeler RM. Histiocytic disorders of children and adults: Introduction to the problem, overview, historical perspective and epidemiology. In: Egeler M, Weitzman S, editors. Histiocytic disorders of children and adults. Cambridge: Cambridge University Press; 2005. pp. 1-13.
2. KambouchnerM, Colby TV, Domenge C, et al. Erdheim-Chester disease with prominent pulmonary involvement associated with eosinophilic granuloma of mandibular bone. Histopathology 1997; 30:353-358. (Pubitemid 27168796)
3. Aouba A, Larousserie F, Le-Guern V, et al. Spumous histiocytic oligoarthritis coexisting with systemic Langerhans' cell histiocytosis: Case report and literature review. Joint Bone Spine 2009; 76:701-704.
4. Karis J, Bernstrand C, Fadeel B, Henter J-I. The incidence of Langerhans cell histiocytosis in children in Stockholm Count, Sweden 1992-2001. In: Proceedings of the XIX Meeting of the Histiocyte Society, Philadelphia; 2003. p. 21.
5. Beverley PCL, Egeler RM, Arceci R, Pritchard J. The Nikolas Symposia and histiocytosis. Nat Rev Cancer 2005; 5:488-494. (Pubitemid 40791491)
6. Aouba A, Georgin Lavialle S, Pagnoux C, et al. Rationale and efficacy of interleukin-1 targeting in Erdheim-Chester disease. Blood 2010; 116:4070-4076.
7. Jaffe R. The diagnostic histopathology of Langerhans cell histiocytosis. In: Egeler M, Weitzman S, editors. Histiocytic disorders of children and adults. Cambridge: Cambridge University Press; 2005. pp. 14-39.
8. Birbeck F, Breathnach AS, Everall JD. An electron microscopic study of basal melanocytes and high-level clear cells (Langerhans' cells) in vitiligo. J Invest Dermatol 1961; 37:51-64.
9. Willman CL. Detection of clonal histiocytes in Langerhans cell histiocytosis: Biology and clinical significance. Br J Cancer Suppl 1994; 23:S29-S33. (Pubitemid 24275535)
10. Arico M, Nichols K, Whitlock JA, et al. Familial clustering of Langerhans cell histiocytosis. Br J Haematol 1999; 107:883-888. (Pubitemid 30020164)
11. Bechan GI, Meeker AK, De Marzo AM, et al. Telomere length shortening in Langerhans cell histiocytosis. Br J Haematol 2008; 140:420-428.
12. Schouten B, Egeler RM, Leenen P, et al. Expression of cell cycle-related gene products in Langerhans cell histiocytosis. J Pediatr Hematol Oncol 2002; 24:727-732. (Pubitemid 35448737)
13. Rodig S, Payne E, Degar B, et al. Aggressive Langerhans cell histiocytosis following T-ALL: Clonally related neoplasms with persistent expression of constitutively active NOTCH1. Am J Hematol 2008; 83:116-121.
14. Badalian Very G, Vergilio J, Degar B, et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood 2010; 116:1919-1923. This presents novel data on the presence of mutations in the BRAF protooncogene in LCH supporting both the neoplastic hypothesis and suggesting opportunity for therapeutic targeting of the BRAF pathway.
15. Coury F, Annels N, Rivollier A, et al. Langerhans cell histiocytosis reveals a new IL-17A-dependent pathway of dendritic cell fusion. Nat Med 2008; 14:81-87.
16. Allen C, McClain K. Interleukin-17A is not expressed by CD207(+) cells in Langerhans cell histiocytosis lesions. Nat Med 2009; 15:483-485.
17. Coppes-Zantinga A, Egeler RM. The Langerhans cell histiocytosis X files revealed. Br J Haematol 2002; 116:3-9. (Pubitemid 34122058)
18. Broadbent V, Gadner H. Current therapy for Langerhans cell histiocytosis. Hematol Oncol Clin North Am 1998; 12:327-338. (Pubitemid 28175883)
19. Donadieu J, Egeler RM, Pritchard J. Langerhans cell histiocytosis: A clinical update. In: Egeler M, Weitzman S, editors. Histiocytic disorders of children and adults. Cambridge: Cambridge University Press; 2005. pp. 95-129.
20. Kilpatrick SE, Wenger DE, Gilchrist GS, et al. Langerhans' cell histiocytosis (histiocytosis X) of bone. A clinicopathologic analysis of 263 pediatric and adult cases. Cancer 1995; 76:2471-2484.
21. Phillips M, Allen C, Gerson P, McClain K. Comparison of FDG-PET scans to conventional radiography and bone scans in management of Langerhans cell histiocytosis. Pediatr Blood Cancer 2009; 52:97-101.
22. Sapkas G, Papadakis M. Vertebral Langerhans cell histiocytosis in an adult patient: Case report and review of the literature. Acta Orthop Belg 2011; 77:260-264.
23. Grois N, Fahrner B, Arceci R, et al. Central nervous system disease in Langerhans cell histiocytosis. J Pediatr 2010; 156:873-881.
24. Yasko AW, Fanning CV, Ayala AG, et al. Percutaneous techniques for the diagnosis and treatment of localized Langerhans-cell histiocytosis (eosinophilic granuloma of bone). J Bone Joint Surg Am 1998; 80:219-228. (Pubitemid 28103386)
25. Morimoto A, Shioda Y, Imamura T, et al. Nationwide survey of bisphosphonate therapy for children with reactivated Langerhans cell histiocytosis in Japan. Pediatr Blood Cancer 2011; 56:110-115. This presents data on the safety and effectiveness of bisphosphonates in children with reactivated bony LCH and reinforces the need for large, prospective trials of this therapy.
26. Gadner H, Ladisch S. The treatment of Langerhans cell histiocytosis. In: Egeler M, Weitzman S, editors. Histiocytic disorders of children and adults. Cambridge: Cambridge University Press; 2005. pp. 229-253.
27. Montero AJ, Daz-Montero CM, Malpica A, et al. Langerhans cell histiocytosis of the female genital tract: A literature review. Int J Gynecol Cancer 2003; 13:381-388. (Pubitemid 38222592)
28. Kwon OS, Cho KH, Song KY. Primary cutaneous Langerhans cell histiocytosis treated with photochemotherapy. J Dermatol 1997; 24:54-56. (Pubitemid 27097207)
29. Titgemeyer C, Grois N, Minkov M, et al. Pattern and course of single-system disease in Langerhans cell histiocytosis data from the DAL-HX 83 and 90- study. Med Pediatr Oncol 2001; 37:108-114. (Pubitemid 32738071)
30. Ceci A, de Terlizzi M, Colella R, et al. Langerhans cell histiocytosis in childhood: Results from the Italian cooperative AIEOP-CNR-H.X '83 study. Med Pediatr Oncol 1993; 21:259-264. (Pubitemid 23117151)
31. Gadner H, Heitger A, Grois N, et al. Treatment strategy for disseminated Langerhans cell histiocytosis. DAL HX-83 study group. Med Pediatr Oncol 1994; 23:72-80. (Pubitemid 24213319)
32. Gadner H, Grois N, Arico M, et al. A randomized trial of treatment for multisystem Langerhans' cell histiocytosis. J Pediatr 2001; 138:728-734. (Pubitemid 32417676)
33. Gadner H, Grois N, Potschger U, et al. Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification. Blood 2008; 111:2556-2562.
34. Morimoto A, Ikushima S, Kinugawa N, et al. Improved outcome in the treatment of pediatric multifocal Langerhans cell histiocytosis: Results from the Japan Langerhans cell histiocytosis study group-96 protocol study. Cancer 2006; 107:613-619. (Pubitemid 44107223)
35. Bernard F, Thomas C, Bertrand Y, et al. Multicentre pilot study of 2-chlorodeoxyadenosine and cytosine arabinoside combined chemotherapy in refractory Langerhans cell histiocytosis with haematological dysfunction. Eur J Cancer 2005; 41:2682-2689. (Pubitemid 41607559)
36. Apollonsky N, Lipton J. Treatment of refractory Langerhans cell histiocytosis (LCH) with a combination of 2-chlorodeoxyadenosine and cytosine arabinoside. J Pediatr Hematol Oncol 2009; 31:53-56.
37. Imamura T, Sato T, Shiota Y, et al. Outcome of pediatric patients with Langerhans cell histiocytosis treated with 2 chlorodeoxyadenosine: A nationwide survey in Japan. Int J Hematol 2010; 91:646-651.
38. Campbell PK, Abraham A, Jeng M, et al. Use of clofarabine in the treatment of refractory and recurrent multisystem Langerhans cell histiocytosis. Pediatr Blood Cancer 2011; 56:691-692.
39. Caselli D, Arico M. The role of BMT in childhood histiocytoses. Bone Marrow Transplant 2008; 41 (Suppl 2):S8-S13. (Pubitemid 351864699)
40. Steiner M, Matthes Martin S, Attarbaschi A, et al. Improved outcome of treatment-resistant high-risk Langerhans cell histiocytosis after allogeneic stem cell transplantation with reduced-intensity conditioning. Bone Marrow Transplant 2005; 36:215-225. (Pubitemid 41136293)
41. Kudo K, Ohga S, Morimoto A, et al. Improved outcome of refractory Langerhans cell histiocytosis in children with hematopoietic stem cell transplantation in Japan. Bone Marrow Transplant 2010; 45:901-906.
42. Weitzman S, Whitlock J. Uncommon histiocytic disorders: The non-Langerhans cell histiocytoses. In: Egeler M, Weitzman S, editors. Histiocytic disorders of children and adults. Cambridge: Cambridge University Press; 2005. pp. 293-320.
43. Rush WL, Andriko JA, Galateau Salle F, et al. Pulmonary pathology of Erdheim-Chester disease. Mod Pathol 2000; 13:747-754. (Pubitemid 30470164)
44. Al Quran S, Reith J, Bradley J, Rimsza L. Erdheim-Chester disease: Case report, PCR-based analysis of clonality, and review of literature. Mod Pathol 2002; 15:666-672. (Pubitemid 34666471)
45. Chetritt J, Paradis V, Dargere D, et al. Chester-Erdheim disease: A neoplastic disorder. Hum Pathol 1999; 30:1093-1096. (Pubitemid 29427167)
46. Arnaud L, Gorochov G, Charlotte F, et al. Systemic perturbation of cytokine and chemokine networks in Erdheim-Chester disease: A single-center series of 37 patients. Blood 2011; 117:2783-2790.
47. Haroche J, Amoura Z, Charlotte F, et al. Imatinib mesylate for platelet-derived growth factor receptor-beta-positive Erdheim-Chester histiocytosis. Blood 2008; 111:5413-5415.
48. Veyssier-Belot C, Cacoub P, Caparros-Lefebvre D. Erdheim-Chester disease: Clinical and radiologic characteristics of 59 cases. Medicine 1996; 75:157-169. (Pubitemid 26159212)
49. Gupta A, Aman K, Al Babtain M, et al. Multisystem Erdheim-Chester disease a unique presentation with liver and axial skeletal involvement. Br J Haematol 2007; 138:280. (Pubitemid 47035384)
50. Ivan D, Neto A, Lemos L, Gupta A. Erdheim-Chester disease: A unique presentation with liver involvement and vertebral osteolytic lesions. Arch Pathol Lab Med 2003; 127:e337-e339.
51. Klieger M, Schultz E, Elkowitz D, et al. Erdheim-Chester disease: A unique presentation with multiple osteolytic lesions of the spine and pelvis that spared the appendicular skeleton. AJR Am J Roentgenol 2002; 178:429-432. (Pubitemid 34098054)
52. Caparros Lefebvre D, Pruvo JP, Remy M, et al. Neuroradiologic aspects of Chester-Erdheim disease. AJNR Am J Neuroradiol 1995; 16:735-740.
53. Fortman BJ, Beall DP. Erdheim-Chester disease of the retroperitoneum: A rare cause of ureteral obstruction. AJR Am J Roentgenol 2001; 176:1330-1331. (Pubitemid 32323287)
54. Sanchez J, Mora C, Macia M, Navarro J. Erdheim-Chester disease as cause of end-stage renal failure: A case report and review of the literature. Int Urol Nephrol 2010; 42:1107-1112.
55. Gupta A, Kelly B, McGuigan J. Erdheim-Chester disease with prominent pericardial involvement: Clinical, radiologic, and histologic findings. Am J Med Sci 2002; 324:96-100. (Pubitemid 34851732)
56. Haroche J, Amoura Z, Dion E, et al. Cardiovascular involvement, an overlooked feature of Erdheim-Chester disease: Report of 6 new cases and a literature review. Medicine 2004; 83:371-392. (Pubitemid 39541113)
57. Myra C, Sloper L, Tighe PJ, et al. Treatment of Erdheim-Chester disease with cladribine: A rational approach. Br J Ophthalmol 2004; 88:844-847. (Pubitemid 38725610)
58. Alharthi M, Calleja A, Panse P, et al. Multimodality imaging showing complete cardiovascular involvement by Erdheim-Chester disease. Eur J Echocardiogr 2010; 11:E25-E125.
59. Boissel N, Wechsler B, Leblond V. Treatment of refractory Erdheim-Chester disease with double autologous hematopoietic stem-cell transplantation. Ann Intern Med 2001; 135:844-845. (Pubitemid 33051276)
60. Eyigor S, Kirazli Y, Memis A, Basdemir G. Erdheim-Chester disease: The effect of bisphosphonate treatment - a case report. Arch Phys Med Rehabil 2005; 86:1053-1057. (Pubitemid 40692378)
61. Srikulmontree T, Massey HD, Roberts WN. Treatment of skeletal Erdheim- Chester disease with zoledronic acid: Case report and proposed mechanisms of action. Rheumatol Int 2007; 27:303-307. (Pubitemid 46088264)
62. Braiteh F, Boxrud C, Esmaeli B, Kurzrock R. Successful treatment of Erdheim- Chester disease, a non-Langerhans-cell histiocytosis, with interferonalpha. Blood 2005; 106:2992-2994.
63. Jeon I, Lee S, Lee M. Chemotherapy and interferon-alpha treatment of Erdheim-Chester disease. Pediatr Blood Cancer 2010; 55:745-747.
64. Suzuki H, Hosoya N, Miyagawa K, et al. Erdheim-Chester disease: Multisystem involvement and management with interferon-alpha. Leuk Res 2010; 34:e21-e24.
65. Luft T, Pang KC, Thomas E, et al. Type I IFNs enhance the terminal differentiation of dendritic cells. J Immunol 1998; 161:1947-1953. (Pubitemid 28387618)
66. Arnaud L, Hervier B, Nel A, et al. CNS involvement and treatment with interferon-a are independent prognostic factors in Erdheim-Chester disease: A multicenter survival analysis of 53 patients. Blood 2011; 117:2778-2782.
67. Haroche J, Amoura Z, Trad S, et al. Variability in the efficacy of interferon-alpha in Erdheim-Chester disease by patient and site of involvement: Results in eight patients. Arthritis Rheum 2006; 54:3330-3336. (Pubitemid 44622105)
68. Janku F, Amin H, Yang D, et al. Response of histiocytoses to imatinib mesylate: Fire to ashes. J Clin Oncol 2010; 28:e633-e636.